
ANGIODYNAMICS INC
ANGONASDAQTrading Snapshot
- Day Range
- $15.68 β $15.98
- 52-Week Range
- $8.36 β $16.05
- Volume
- $2.73B
- Avg Volume
- $2.23B
- Shares Outstanding
- 41.3M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $320M
- Last Q Revenue
- $87M
- P/E Ratio
- β
- P/S Ratio
- 2.0x
- EPS (TTM)
- $-0.89
- Dividend Yield
- β
Why Investors Own ANGO
- βHigh-growth profile β revenue up +59.2% YoY with expanding US Equity exposure.
- βHealthy economics β 33% gross margin and 13% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ANGIODYNAMICS INC
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
ANGIODYNAMICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ANGO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ANGIODYNAMICS INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.